Seegene Opens France Subsidiary to Support Global Growth

Seegene, Inc., a global leader in molecular diagnostics (MDx), announced the establishment of a new subsidiary in France to reinforce its European presence and support global sales expansion.

The new subsidiary will strengthen local engagement with customers and partners through enhanced technical support, market development and collaboration with healthcare stakeholders.

"On the French market, which is divided between the private and public sectors, the ability to quickly deliver innovative products and meet laboratories' efficiency needs is a key factor for competitiveness," said Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene. "The subsidiary will enable Seegene to gain a better understanding the French healthcare landscape, strengthening local customer service, and accelerate the growth of the company's in vitro diagnostics business with dedicated local expertise."

The subsidiary also provides a strategic foothold for the European rollout of Seegene's solutions that are in development, CURECA™, a fully automated, unmanned PCR system, and STAgora™, a real-time diagnostic data analytics and predictive insights platform.

The addition of France brings Seegene's overseas sales subsidiaries to eight, complementing its global distribution network of 90 distributors across 94 countries.

As of the first half of 2025, overseas sales accounted for approximately 93 percent of Seegene's total revenue, with Europe representing 63 percent. The region remains a key growth driver for the company's global expansion roadmap.